6. RIFERIMENTI BIBLIOGRAFICI.
- 1) Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC. (2007). The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 114:97-109
- 2) Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987-96
- 3) Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110.
- 4) Chin L, Hahn WC, Getz G, Meyerson M. (2012). Making sense of cancer genomic data. Genes Dev.25:534-55.
- 5) Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. (1999). Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615– 2622.
- 6) Orlowski RZ, Kuhn DJ. (2008). Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 14:1649-57.
- 7) Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. (1998). Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 58:4342-8.
- 8) Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL, Magdelénat H. (1998). The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer. 77:1103-7.
- 9) Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR. (2002). A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 8:2505–11.
- 10) Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL. (2002). Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 20:4420–7.
- 11) Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. (2004). Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J
- 12) Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, Wright J, Kantarjian H. (2004). Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 10:3371–6.
- 13) Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC. (2004). Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol. 22:4804–9.
- 14) Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA. (2005). A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res. 11:3410–6. - 15) Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S,
Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 348:2609–17.
- 16) Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC. (2005). Risk factors and kinetics of thrombocytopenia
associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 106:3777–84.
- 17) Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. (2006). Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 24:3113–20. - 18) Vogelstein B, Kinzler KW. (2004).Cancer genes and the pathways they
control. Nat Med. 10:789–99.
- 19) Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303:844–8.
- 20) Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. (2006). Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 108:993–1000.
- 21) Stühmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, Theurich S, Cigliano L, Manz RA, Daniel PT, Bommert K, Vassilev LT, Bargou RC. (2005). Stühmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 106:3609-17.
- 22) Villalonga-Planells R, Coll-Mulet L, Martínez-Soler F, Castaño E, Acebes JJ, Giménez-Bonafé P, Gil J, Tortosa A. (2011). Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One. 6:e18588.
- 23) Shangary S, Wang S. (2009). Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate MDM2-p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol. 49: 223-41
- 24) Matsuda S, Rouault J, Magaud J, Berthet C. (2001). In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS. 497:67–72.
- 25) Tirone F. (2001). The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair? J Cell Physiol. 187:155-65.
- 26) Winkler GS. (2010). The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol. 222:66-72.
- 27) Collart MA, Timmers HT. (2004). The eukaryotic Ccr4-not complex: a regulatory platform integrating mRNA metabolism with cellular signaling pathways? Prog Nucleic Acid Res Mol Biol. 77:289-322.
- 28) Goldstrohm AC, Wickens M. (2008). Multifunctional deadenylase complexes diversify mRNA control. Nat Rev Mol Cell Biol. 9:337-44.
- 29) Passeri D, Marcucci A, Rizzo G, Billi M, Panigada M, Leonardi L, Tirone F, Grignani F. (2006). Btg2 enhances retinoic acid-induced differentiation by modulating histone H4 methylation and acetylation. Mol Cell Biol. 26:5023-32.
- 30) Pre´vot, D., A. P. Morel, T. Voeltzel, M. C. Rostan, R. Rimokh, J. P. Magaud, and L. Corbo. (2001). Relationships of the antiproliferative
proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex: involvement in estrogen receptor alpha signalling pathway. J. Biol. Chem. 276:9640–9648.
- 31)Guardavaccaro D, Corrente G, Covone F, Micheli L, D'Agnano I,
Starace G, CarusoM, Tirone F. (2000). Arrest of G(1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. Mol Cell Biol. 20:1797±1815.
- 32) Prevot D, Voeltzel T, Birot AM, Morel AP, Rostan MC, Magaud JP. Corbo L. (2000). The leukemia-associated protein Btg1 and the p53-regulated protein Btg2 interact with the homeoprotein Hoxb9and enhance its transcriptional activation. J Biol Chem. 275:147±153.
- 33) Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco MM, Wijendran V, Shioda T, Sgroi D, Donahoe PK, Maheswaran S. (2010). HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci U S A. 107:1100-5.
- 34) Kawakubo H, Brachtel E,Hayashida T, Yeo G, Kish J, Muzikansky A, Walden PD, Maheswaran S. (2006). Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res. 66:7075–7082.
- 35) Möllerström E, Delle U, Danielsson A, Parris T, Olsson B, Karlsson P, Helou K. (2010). High-resolution genomic profiling to predict 10-year overall survival in node-negative breast cancer. Cancer Genet Cytogenet. 198:79-89.
- 36) LinWJ, Chang YF,Wang WL, Huang CY. (2001). Mitogen-stimulated TIS21 protein interacts with a protein-kinase-Calpha-binding protein rPICK1. Biochem J. 354:635–643.
- 37) Ryu MS, Lee MS, Hong JW, Hahn TR, Moon E, Lim IK. (2004). TIS21/BTG2/PC3 is expressed through PKC-delta pathway and inhibits binding of cyclin B1-Cdc2 and its activity, independent of p53 expression. Exp Cell Res. 299:159-70.
- 38) Hong JW, Ryu MS, Lim IK. (2005). Phosphorylation of serine 147 of tis21/BTG2/pc3 by p-Erk1/2 induces Pin-1 binding in cytoplasm and cell death. J Biol Chem. 280:21256–21263.
- 39) Keith Wheaton, Jennifer Muir, Weili Ma, Benchimo S. (2010). BTG2 antagonizes Pin1 in response to mitogens and telomere disruption during replicative senescence. Aging Cell. 9:747-60.
- 40) Lee TH, Tun-Kyi A, Shi R, Lim J, Soohoo C, Finn G, Balastik M, Pastorino L, Wulf G, Zhou XZ, Lu KP. (2009). Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance. Nat.Cell Biol. 11: 97– 105.
- 41) Lim IK. (2006). TIS21 ⁄ BTG2 ⁄ PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule. J. Cancer Res. Clin. Oncol. 132: 417–426.
- 43) Iacopetti P, Michelini M, Stuckmann I, Oback B, Aaku-Saraste E,Huttner WB. (1999). Expression of the antiproliferative gene TIS21at the onset of neurogenesis identi®es single neuroepithelial cells that switch from proliferative to neuron-generating division. Proc Natl Acad Sci USA 96:4639±4644.
- 44) Farioli-Vecchioli S, Saraulli D, Costanzi M, Pacioni S, Cinà I, Aceti M, Micheli L, Bacci A, Cestari V, Tirone F. (2008). The timing of differentiation of adult hippocampal neurons is crucial for spatial memory. PLoS Biol. 6:e246.
- 45) Farioli-Vecchioli S, Saraulli D, Costanzi M, Leonardi L, Cinà I, Micheli L, Nutini M, Longone P, Oh SP, Cestari V, Tirone F. (2009). Impaired Terminal Differentiation of Hippocampal Granule Neurons and Defective Contextual Memory in PC3/Tis21 Knockout Mice. PLoS ONE. 4:e8339.
- 46) Yanagie H, Tanabe T, Sumimoto H, Sugiyama H, Matsuda S, Nonaka Y, Ogiwara N, Sasaki K, Tani K, Takamoto S, Takahashi H, Eriguchi M. (2009). Tumor growth suppression by adenovirus-mediated introduction of a cell-growth-suppressing gene tob in a pancreatic cancer model. Biomed Pharmacother. 63:275-86.
- 47) Ficazzola MA, Fraiman M, Gitlin J, Woo K, Melamed J, Rubin MA, Walden PD. (2001). Antiproliferative B cell translocation gene 2 protein is down-regulated posttranscriptionally as an early event in prostate carcinogenesis. Carcinogenesis. 22:1271–1279.
- 48) Ito Y, Suzuki T, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Yamamoto T, Miyauchi A. (2005). Phosphorylation and inactivation of Tob contributes to the progression of papillary carcinoma of the thyroid. Cancer Lett, 220:237–242. - 49) Iwanaga K, SueokaN, Sato A, Sakuragi T, Sakao Y, Tominaga M,
tob, a novel tumor suppressor gene product, is an early event in lung cancer. Cancer Lett. 202:71–79.
- 50) Kawakubo, H., J. L. Carey, E. Brachtel, V. Gupta, J. E. Green, P. D. Walden,and S. Maheswaran. (2004). Expression of the NF-_B-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene. 23:8310–8319 - 52) Struckmann, K., P. Schraml, R. Simon, K. Elmenhorst, M. Mirlacher, J. (2004). BTG2 expression modulaes histone H4 methylation 5031 Kononen, and H. Moch. 2004. Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. Cancer Res. 64:1632–1638.
- 53) Calzolari F, Appolloni I, Tutucci E, Caviglia S, Terrile M, Corte G, Malatesta P. (2008). Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. Neoplasia. 10:1373-82.
- 54) Rouault JP, Falette N, Guehennuux F, Guillot C, Rimokh R, Wang Q,Berthet C, Moyret-Lalle C, Savatier P, Pain B, Shaw P, Berger R,Samarut J, Magaud JP, Ozturk M, Samarut C, Puisieux A. (1996). Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 14:482±486.
- 55) Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI,Williams BR, Gudkov AV. (2006). A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev. 20:236–252.
- 56) Duriez, C., N. Falette, C. Audoynaud, C. Moyret-Lalle, K. Bensaad, S. Courtois, Q. Wang, T. Soussi, and A. Puisieux. (2002). The human
BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene. 282:207–214.
- 57) Bradbury A, Possenti R, Shooter EM, Tirone F. (1991). Molecular cloning of PC3, a putatively secreted protein whose mRNA is induced by nerve growth factor and depolarization. Proc Natl Acad Sci USA. 88:3353±3357.
- 58) Sukhatme VP, Kartha S, Toback FG, Taub R, Hoover RG, Tsai-Morris CH. (1987). A novel early growth response gene rapidly induced by fibroblast, epithelial cell and lymphocyte mitogens. Oncogene Res. 1:343-55. - 59) Cho K, Wang X, Nie S, Chen ZG, Shin DM. (2008). Therapeutic
nanoparticles for drug delivery in cancer. Clin Cancer Res. 14:1310-6. - 60) Donato LJ, Suh JH, Noy N. (2007). Suppression ofmammary carcinoma
cell growth by retinoic acid: The cell cycle control gene Btg2 is a direct target for retinoic acid receptor signaling. Cancer Res. 67:609–615.
- 61) Villalonga-Planells R, Coll-Mulet L, Martínez-Soler F, Castaño E, Acebes JJ, Giménez-Bonafé P, Gil J, Tortosa A. (2011). Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One. 6:e18588.
- 62) Fan WH, Hou Y, Meng FK, Wang XF, Luo YN, Ge PF. (2011). Proteasome inhibitor MG-132 induces C6 glioma cell apoptosis via oxidative stress. Acta Pharmacol Sin. 32:619-25.
- 63) Ko JK, Choi CH, Kim YK, Kwon CH. (2011). The proteasome inhibitor MG-132 induces AIF nuclear translocation through down-regulation of ERK and Akt/mTOR pathway. Neurochem Res. 36:722-31.
- 64) Sasajima H, Nakagawa K, Yokosawa H. (2002). Antiproliferative proteins of the BTG/Tob family are degraded by the ubiquitin-proteasome system. Eur J Biochem. 269:3596-604.
- 65) Ceruti S, Mazzola A, Abbracchio MP. (2006). Proteasome inhibitors potentiate etoposide-induced cell death in human astrocytoma cells bearing a mutated p53 isoform. J Pharmacol Exp Ther. 319:1424-34.
- 66) Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguría A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M. (2005). Tumour biology: senescence in premalignant tumours. Nature. 436:642.
- 67) Miller CR, Perry A. (2007). Glioblastoma. Arch Pathol Lab Med. 131:397-406.
- 68) Bartek J Jr, Ng K, Bartek J, Fischer W, Carter B, Chen CC. (2012). Key concepts in glioblastoma therapy. J Neurol Neurosurg Psychiatry. 83:753-60.
- 69) Welch M, Lai R. (2009). Glioblastoma multiforme. Curr Treat Options Neurol. 11:297-305.
- 70) Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, Ron D, Yin XM. (2007). Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol. 171:513-24.
- 71) Karve TM, Rosen EM. (2012). B-cell translocation gene 2 (BTG2) stimulates cellular antioxidant defenses through the antioxidant transcription factor NFE2L2 in human mammary epithelial cells. J Biol Chem. 287:31503-14.
- 72) Lim IK, Lee MS, Ryu MS, Park TJ, Fujiki H, Eguchi H, Paik WK. (1998). Induction of growth inhibition of 293 cells by downregulation of the cyclin E and cyclin-dependent kinase 4 proteins due to overexpression of TIS21. Mol Carcinog. 23:25-35.
- 73) Yeh ES, Means AR. (2007). PIN1, the cell cycle and cancer. Nat. Rev. Cancer 7:381–388.
- 74) Fujimori F, Takahashi K, Uchida C, Uchida T. (1999). Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest. Biochem. Biophys. Res. Commun. 265:658–663.
- 75) You H, Zheng H, Murray SA, Yu Q, Uchida T, Fan D, Xiao ZX. (2002). IGF-1 induces Pin1 expression in promoting cell cycle S-phase entry. J. Cell. Biochem. 84:211–216.
